Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656349 | 0.73 | HSD11B1 (0.33) | — | |
| SCHEMBL11216029 | 0.71 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAALDH1A1TSHR | |
| SCHEMBL11692474 | 0.69 | SMN1; SMN2 (0.44) | SMN1; SMN2TLR8LMNAKMT2AALDH1A1 | |
| SCHEMBL9277178 | 0.68 | MAPK13 (0.35) | SMN1; SMN2 | |
| SCHEMBL11376315 | 0.64 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAKMT2AALDH1A1TSHR | |
| SCHEMBL5657269 | 0.63 | TSHR (0.36) | TDP1TSHR | |
| SCHEMBL11212263 | 0.62 | SMN1; SMN2 (0.41) | SMN1; SMN2LMNAKMT2AALDH1A1TDP1 | |
| SCHEMBL24077904 | 0.61 | ROCK2 (0.48) | LMNAALDH1A1TDP1TSHR | |
| SCHEMBL14204101 | 0.61 | SMPD1 (0.34) | SMN1; SMN2TLR8LMNAKMT2AALDH1A1 | |
| SCHEMBL11337639 | 0.60 | KMT2A (0.44) | SMN1; SMN2TLR8LMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | SMN1; SMN2 1174/4885TLR8 4213/4885LMNA 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.